Weekly Recap: AP02 Phase 1 PK results and AURA Phase 2 enrollment
Avalyn Pharma Inc (NASDAQ:AVLN) reported Phase 1 data for nebulized AP02 showing higher lung and lower systemic exposure than oral nintedanib, and is now enrolling patients in the AURA Phase 2 IPF trial as recruitment and operations move forward.Previous Week RecapThis is an AI-generated summary an…